Greg Mohl

Greg Mohl, Kampmann Lab

[email protected]

Graduate Student, Tetrad

Education:

B.S. in Microbiology, Brigham Young University

Publications:

  • Mohl, G., Liddle, N., Nygaard, J., Dorius, A., Lyons, N., Hodek, J., Weber, J., Michaelis, D., Busath, D. (2019). Novel influenza inhibitors designed to target PB1 interactions with host importin RanBP5. Antiviral Research,164, 81-90. doi:10.1016/j.antiviral.2019.02.003
  • Gordon, N, Mcguire, K., Wallentine, S., Mohl, G., Lynch, J., Harrison, R., & Busath, D. (2017). Divalent copper complexes as influenza A M2 inhibitors. Antiviral Research, 147, 100-106. doi:10.1016/j.antiviral.2017.10.009.

Research Experience:

  • Busath Lab, Department of Physiology and Developmental Biology, Brigham Young University Feb. 2015-May 2018
    Developed novel inhibitors of the influenza virus using in silico modeling and in vitro validation.
  • Tolero Pharmaceuticals May 2017-Aug. 2017
    Optimized a companion diagnostic approach for chemotherapy and tested mechanisms of preclinical drugs.

Honors and Awards:

  • Outstanding Research Award – Department of Microbiology and Molecular Biology, Brigham Young University (2018)
  • Undergraduate Research Award – Department of Chemistry and Biochemistry, Brigham Young University (2017 and 2018)

Teaching Experience:

  • Organic Chemistry Lab TA August 2015-May 2016.
  • Organic Chemistry Lab Student Instructor June 2016-April 2017
  • Molecular Dynamics TA January-April 2018

Research Interests:

Cells have to constantly monitor the quality of many different processes, including metabolism, genome integrity, and protein-folding capacity. These many inputs converge on a few signaling pathways that lead to pro-survival or pro-apoptotic stress responses. I’m interested in understanding how these stress responses play a role in neurodegenerative diseases. Specifically, the molecular mechanisms by which Tau causes toxicity in diseased neurons are still unknown. I will use functional genomics, cell biology, and biochemistry to understand these molecular mechanisms, which may lead to novel therapeutic approaches in several neurodegenerative indications.